相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ
David A. Hilton et al.
HISTOPATHOLOGY (2009)
Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol 3-Kinase and Reduces Metastasis in Human Colon Carcinoma
Jing Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
Miguel A. Lopez-Lago et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth
Marianne F. James et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas
D. Lallemand et al.
ONCOGENE (2009)
Magic but treatable? Tumours due to loss of Merlin
C. O. Hanemann
BRAIN (2008)
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma
Sylwia Ammoun et al.
CANCER RESEARCH (2008)
Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas
Halldora K. Thorarinsdottir et al.
CLINICAL CANCER RESEARCH (2008)
Neuregulin-1, a Key Axonal Signal that Drives Schwann Cell Growth and Differentiation
Carmen Birchmeier et al.
GLIA (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain
Brunilde Gril et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
ErbB and Nrg: Potential molecular targets for vestibular schwannoma pharmacotherapy
Joni K. Doherty et al.
OTOLOGY & NEUROTOLOGY (2008)
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: A preliminary study
J. Jason Clark et al.
OTOLOGY & NEUROTOLOGY (2008)
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy
Scott R. Plotkin et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Opinion - Survivin, cancer networks and pathway-directed drug discovery
Dario C. Altieri
NATURE REVIEWS CANCER (2008)
Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells
M-H Wang et al.
JOURNAL OF PATHOLOGY (2007)
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin
Marcello Curto et al.
JOURNAL OF CELL BIOLOGY (2007)
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
Filippo Montemurro et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac
Helen Morrison et al.
CANCER RESEARCH (2007)
Differential gene expression between human schwannoma and control Schwann cells
C. O. Hanemann et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2006)
Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases
Sassan Hafizi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
The tumor suppressors merlin and expanded function cooperatively to modulate receptor endocytosis and signaling
S Maitra et al.
CURRENT BIOLOGY (2006)
Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers
WL Xia et al.
CANCER RESEARCH (2006)
Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis
MS Stonecypher et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells
H Asanuma et al.
CANCER RESEARCH (2005)
The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer (vol 12, pg 705, 2005)
YG Fan et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway
Q Wang et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Benign tumors from the human nervous system express high levels of survivin and are resistant to spontaneous and radiation-induced apoptosis
M Hassounah et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
RON, a tyrosine kinase receptor involved in tumor progression and metastasis
ER Camp et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases
XL Qian et al.
EMBO JOURNAL (2004)
Expression of neuregulin and activation of erbB receptors in vestibular schwannomas: Possible autocrine loop stimulation
MR Hansen et al.
OTOLOGY & NEUROTOLOGY (2004)
The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation
D Angeloni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells
K Kaempchen et al.
HUMAN MOLECULAR GENETICS (2003)
Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway
JY Lim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
分享论文
